Neuroactive Steroids in Acute Ischemic Stroke: Association with Cognitive, Functional, and Neurological Outcomes

Abstract

Despite several scientific and technological advances, there is no single neuroprotective treatment that can reverse the brain damage after acute ischemic stroke (AIS). Neuroactive steroids are cholesterol-derived hormones that have the ability to modulate the normal and pathologic nervous system employing genomic and nongenomic mechanisms. In this work, we first investigated if AIS affects the plasma concentration of 5 neuroactive steroids (cortisol, estradiol, progesterone, testosterone, and 3α-androstenediol glucuronide). Second, we studied if levels of circulating steroids associate with neurological, cognitive, and functional outcome in a cohort of 60- to 90 year-old male and female patients with AIS. For this purpose, we recruited patients who were hospitalized at the Emergency Room of the Central Military Hospital within the first 24 h after stroke onset. We designed 2 experimental groups, each one composed of 30 control subjects and 30 AIS patients, both males and females. The assessment of neurological deficit was performed with the NIHSS and the tests used for the functional and cognitive status were: (1) modified Rankin Scale; (2) Photo test, and (3) abbreviated Pfeiffer’s mental status questionnaire. We observed a significant difference in plasma concentration of cortisol and estradiol between both experimental groups. In the AIS group, higher levels of these neuroactive steroids were associated with more pronounced neurological, cognitive and functional deficits in women compared to men. We propose that in elderly patients, high levels of circulating neuroactive steroids like cortisol and estradiol could potentiate AIS-mediated neuropathology in the ischemic and penumbra areas.

Key words

neuroactive steroids - acute ischemic stroke - elderly patients - cognitive impairment - functional impairment

• References

• 1 Heron M. Deaths: leading causes for 2007. Natl Vital Stat Rep 2011; 59: 1-95
• 2 Feigin V. Stroke epidemiology in the developing world. Lancet 2005; 365: 2160-2161
• 3 Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8: 355-369
• 4 Kelly-Hayes M, Beiser A, Kase CS, Scaramucci A, D’Agostino RB, Wolf PA. The influence of gender and age on disability following ischemic stroke: the Framingham study. J Stroke Cerebrovasc Dis 2003; 12: 119-126
• 5 Kapral MK, Fang J, Hill MD, Silver F, Richards J, Jaigobin C, Cheung AM. Sex differences in stroke care and outcomes: results from the registry of the Canadian stroke network. Stroke 2005; 36: 809-814
• 6 Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, Khatiwoda A, Lisabeth L. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol 2008; 7: 915-926
• 7 Morrow AL, Porcu P In: Neuroactive Steroids. Price LH, Stolerman I. (eds.). Encyclopedia of Psychopharmacology. Berlin: Springer; 2014
• 8 Porcu P, Barron AM, Frye CA, Walf AA, Yang SY, He XY, Morrow AL, Panzica GC, Melcangi RC. Neurosteroidogenesis today: Novel targets for neuroactive steroid synthesis and action and their relevance for translational research. J Neuroendocrinol 2016; 28: 12351
• 9 Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO task force on stroke and other cerebrovascular disorders. Stroke 1989; 20: 1407-1431
• 10 Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
• 11 Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M. Measurements of Acute Cerebral Infarction: A Clinical Examination Scale. Stroke 1989; 20: 864-870
• 12 Fischer M, Rüegg S, Czaplinski A, Strohmeier M, Lehmann A, Tschan F, Hunziker P, Marsch S. Research Inter-rater reliability of the Full Outline of UnResponsiveness score and the Glasgow Coma Scale in critically ill patients: a prospective observational study. Critical Care 2010; 14: R64
• 13 Radak D, Resanovic I, Isenovic ER. Changes in hypothalamus-pituitary-adrenal axis following transient ischemic attack. Angiology 2014; 65: 723-732
• 14 Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr 1975; 10: 433-441
• 15 Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, Bone I. Improving the Assessment of Outcomes in Stroke Use of a Structured Interview to Assign Grades on the Modified Rankin Scale. Stroke 2002; 33: 2243-2246
• 16 Yu C, An Z, Zhao W, Wang W, Gao C, Liu S, Wang J, Wu J. Sex Differences in Stroke Subtypes, Severity, Risk Factors, and Outcomes among Elderly Patients with Acute Ischemic Stroke. Front Aging Neurosci 2015; 7: 174
• 17 Barugh AJ, Gray P, Shenkin SD, MacLullich AM, Mead GE. Cortisol levels and the severity and outcomes of acute stroke: a systematic review. J Neurol 2014; 261: 533-545
• 18 Baird TA, Parsons MW, Planh T, Butcher KS, Desmond PM, Tress BM, Colman PG, Chambers BR, Davis SM. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 2003; 34: 2208-2214
• 19 Sapolsky RM. Glucocorticoid Toxicity in the Hippocampus: Reversal by Supplementation with Brain Fuels. The Journal of Neuroscience 1986; 6: 2240-2244
• 20 Herman JP, Schäfer MK, Young EA, Thompson R, Douglass J, Akil H, Watson SJ. Evidence for hippocampal regulation of neuroendocrine neurons of the hypothalamo-pituitary-adrenocortical axis. J Neurosci 1989; 9: 3072-3082
• 21 Kim JJ, Diamond DM. The stressed hippocampus, synaptic plasticity and lost memories. Nat Rev Neurosci 2002; 3: 453-462
• 22 De Kloet ER, Karst H, Joëls M. Corticosteroid hormones in the central stress response: quick-and-slow. Front Neuroendocrinol 2008; 29: 268-272
• 23 McCullough LD, Hurn PD. Estrogen and ischemic neuroprotection: an integrated view. Trends Endocrinol Metab 2003; 14: 228-235
• 24 Yang SH, Liu R, Perez EJ, Wang X, Simpkins JW. Estrogens as protectants of the neurovascular unit against ischemic stroke. Curr Drug Targets CNS Neurol Disord 2005; 4: 169-177
• 25 Sudo S, Wen TC, Desaki J, Matsuda S, Tanaka J, Arai T, Maeda N, Sakanaka M. Beta-estradiol protects hippocampal CA1 neurons against transient forebrain ischemia in gerbil. Neurosci Res 1997; 29: 345-354
• 26 Fukuda K, Yao H, Ibayashi S, Nakahara T, Uchimura H, Fujishima M, Hall ED. Ovariectomy exacerbates and estrogen replacement attenuates photothrombotic focal ischemic brain injury in rats. Stroke 2000; 31: 155-160
• 27 Mendelowitsch A, Ritz MF, Ros J, Langemann H, Gratzl O. 17beta-Estradiol reduces cortical lesion size in the glutamate excitotoxicity model by enhancing extracellular lactate: a new neuroprotective pathway. Brain Res 2001; 901: 230-236
• 28 Azcoitia I, Arevalo MA, De Nicola AF, Garcia-Segura LM. Neuroprotective actions of estradiol revisited. Trends Endocrinol Metab 2011; 22: 467-473
• 29 Velarde MC. Pleiotropic actions of estrogen: a mitochondrial matter. Physiol Genomics 2013; 45: 106-109
• 30 Brinton RD, Yao J, Yin F, Mack WJ, Cadenas E. Perimenopause as a neurological transition state. Nat Rev Endocrinol 2015; 11: 393-405
• 31 DiSilvestro D, Petrosino J, Aldoori A, Melgar-Bermudez E, Wells A, Ziouzenkova O. Enzymatic intracrine regulation of white adipose tissue. Horm Mol Biol Clin Investig 2014; 19: 39-55
• 32 Simpson E, Ackerman G, Smith M, Mendelson C. Estrogen formation in stromal cells of adipose tissue of women: Induction by glucocorticosteroids. Proc Nati Acad Sci USA 1981; 78: 5690-5694
• 33 Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol 2001; 45: 116-124
• 34 Saldanha CJ, Duncan KA, Walters BJ. Neuroprotective Actions of Brain Aromatase. Front Neuroendocrinol 2009; 30: 106-118